References
- Liberra K Lindequist U Marine fungi – a prolific resource of biologically active natural products? Pharmazie 1995 50 9 583 588 7480092
- Belofsky GN Jensen PR Fenical W Sansalvamide: a new cytotoxic cyclic depsipeptide produced by a marine fungus of the genus Fusarium Tetrahedron Lett 1999 40 15 2913 2916
- Du L Zhu T Fang Y Liu H Gu Q Zhu W Aspergiolide A, a novel anthraquinone derivative with naphtho[1,2,3-de]chromene-2,7-dione skeleton isolated from a marine-derived fungus Aspergillus glaucus Tetrahedron 2007 63 5 1085 1088
- Weiss RB The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992 19 6 670 686 1462166
- Hodgson J ADMET – turning chemicals into drugs Nat Biotechnol 2001 19 8 722 726 11479558
- Wang J Comprehensive assessment of ADMET risks in drug discovery Curr Pharm Des 2009 15 19 2195 2219 19601823
- LeBeau JE The role of the LD50 determination in drug safety evaluation Regul Toxicol Pharmacol 1983 3 1 71 74 6612004
- Cook PJ Ju BG Telese F Wang X Glass CK Rosenfeld MG Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions Nature 2009 458 7238 591 596 19234442
- Zunino F Capranico G DNA topoisomerase II as the primary target of anti-tumor anthracyclines Anticancer Drug Des 1990 5 4 307 317 1963303
- Sanguinetti MC Tristani-Firouzi M hERG potassium channels and cardiac arrhythmia Nature 2006 440 7083 463 469 16554806
- Vici P Sergi D Pizzuti L Specificity of action of anticancer agents Clin Ter 2011 162 2 137 149 Italian 21533321
- Teicher BA Newer cytotoxic agents: attacking cancer broadly Clin Cancer Res 2008 14 16 1610 1617 18347161
- Stevens JL Baker TK The future of drug safety testing: expanding the view and narrowing the focus Drug Discov Today 2009 14 3–4 162 167 19100337
- Colbern GT Hiller AJ Musterer RS Pegg E Henderson IC Working PK Significant increase in anticancer potency of doxorubicin Hc1 by its encapsulation in pegylated liposomes J Liposome Res 1999 9 4 523 538
- Aleisa AM Al-Rejaie SS Bakheet SA Effect of metformin on clastogenic and biochemical changes induced by adriamycin in Swiss albino mice Mutat Res 2007 634 1–2 93 100 17693128
- Singh SS Preclinical pharmacokinetics: an approach towards safer and efficacious drugs Curr Drug Metab 2006 7 2 165 182 16472106
- Rousselle C Clair P Lefauconnier JM Kaczorek M Scherrmann JM Temsamani J New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy Mol Pharmacol 2000 57 4 679 686 10727512
- Gharib MI Burnett AK Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis Eur J Heart Fail 2002 4 3 235 242 12034146
- Fagerholm U Prediction of human pharmacokinetics – gastrointestinal absorption J Pharm Pharmacol 2007 59 7 905 916 17637184
- Ke W Zhao Y Huang R Jiang C Pei Y Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system J Pharm Sci 2008 97 6 2208 2216 17879294
- Yee S In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man – fact or myth Pharm Res 1997 14 6 763 766 9210194
- Mahar Doan KM Humphreys JE Webster LO Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs J Pharmacol Exp Ther 2002 303 3 1029 1037 12438524
- Zunino F Pratesi G Perego P Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs Biochem Pharmacol 2001 61 8 933 938 11286984